Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Cipargamin · KAE-609, NITD-609

Small molecule · developed by Novartis Pharmaceuticals

Phase 2 Most advanced trial
NVS Developer

What is Cipargamin?

Cipargamin (KAE609) is an oral capsule agent studied in combination with KLU156 for uncomplicated Plasmodium falciparum malaria.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
KAE-609, NITD-609
Drug type
Small molecule
Therapy area
Infectious disease
Developer
Novartis Pharmaceuticals (NVS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
Z7Q4FWA04P

Conditions studied

Uncomplicated Plasmodium Falciparum Malaria

More from Novartis Pharmaceuticals

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind Cipargamin

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.